MYLAN-ABACAVIR/LAMIVUDINE DIN 02450682
Status: Marketed
Holder: MYLAN PHARMACEUTICALS ULC
Molecule: ABACAVIR (ABACAVIR SULFATE)
Available to quote
Health Canada record
| Active ingredient(s) | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AR02 LAMIVUDINE AND ABACAVIR |
| Original market date | 29-Mar-2016 |
| Current status date | 29-Mar-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Mylan Pharmaceuticals ULC — licence 101774, currently licensed, last inspection rating C (2026-02-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ABACAVIR (ABACAVIR SULFATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02396769 | APO-ABACAVIR | APOTEX INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 300 MG | Marketed |
| 02518287 | APO-ABACAVIR-LAMIVUDINE TABLETS | APOTEX INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Approved |
| 02454513 | AURO-ABACAVIR/LAMIVUDINE | AURO PHARMA INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Marketed |
| 02497654 | JAMP ABACAVIR / LAMIVUDINE | JAMP PHARMA CORPORATION | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Marketed |
| 02480956 | MINT-ABACAVIR | MINT PHARMACEUTICALS INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 300 MG | Marketed |
| 02497808 | MINT-ABACAVIR/LAMIVUDINE | MINT PHARMACEUTICALS INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Approved |
| 02416662 | TEVA-ABACAVIR/LAMIVUDINE | TEVA CANADA LIMITED | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Marketed |
| 02240358 | ZIAGEN | VIIV HEALTHCARE ULC | Solution | ABACAVIR (ABACAVIR SULFATE) 20 MG | Marketed |
| 02399539 | APO-ABACAVIR-LAMIVUDINE | APOTEX INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Dormant |
| 02416255 | APO-ABACAVIR-LAMIVUDINE-ZIDOVUDINE | APOTEX INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 300 MG; LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Cancelled Post Market |
| 02269341 | KIVEXA | VIIV HEALTHCARE ULC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Cancelled Post Market |
| 02458381 | PMS-ABACAVIR-LAMIVUDINE | PHARMASCIENCE INC | Tablet | ABACAVIR (ABACAVIR SULFATE) 600 MG; LAMIVUDINE 300 MG | Dormant |
| 02244757 | TRIZIVIR | VIIV HEALTHCARE ULC | Tablet | ABACAVIR (ABACAVIR SULFATE) 300 MG; LAMIVUDINE 150 MG; ZIDOVUDINE 300 MG | Cancelled Post Market |
| 02240357 | ZIAGEN | VIIV HEALTHCARE ULC | Tablet | ABACAVIR (ABACAVIR SULFATE) 300 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 17941 | 2016-03-29 | Abbreviated New Drug Submission (ANDS) |